CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Moderate Buy” by Analysts

CRISPR Therapeutics AG (NASDAQ:CRSP) has earned an average rating of “Moderate Buy” from the nineteen research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $67.7778.

Several research analysts have weighed in on CRSP shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Monday, April 20th. Truist Financial upgraded shares of CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Piper Sandler reiterated an “overweight” rating and issued a $110.00 price target (up from $105.00) on shares of CRISPR Therapeutics in a research report on Tuesday, March 17th. Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Wednesday, May 27th. Finally, Evercore restated an “outperform” rating and set a $76.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, May 11th.

CRISPR Therapeutics Stock Down 3.1%

CRSP opened at $54.59 on Wednesday. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32. CRISPR Therapeutics has a 1-year low of $44.12 and a 1-year high of $78.48. The company has a market capitalization of $5.26 billion, a PE ratio of -8.78 and a beta of 1.74. The firm’s 50 day simple moving average is $52.66 and its two-hundred day simple moving average is $53.01.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The business had revenue of $1.46 million during the quarter. As a group, equities analysts forecast that CRISPR Therapeutics will post -4.89 EPS for the current year.

Insider Activity at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the sale, the insider directly owned 19,357 shares in the company, valued at $1,076,636.34. This trade represents a 16.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.10% of the stock is owned by insiders.

Institutional Trading of CRISPR Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CRSP. Royal Bank of Canada raised its position in shares of CRISPR Therapeutics by 28.2% during the 1st quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock valued at $4,856,000 after purchasing an additional 31,392 shares during the period. AQR Capital Management LLC bought a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at $861,000. Woodline Partners LP raised its position in shares of CRISPR Therapeutics by 34.3% during the 1st quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock valued at $4,645,000 after purchasing an additional 34,883 shares during the period. Prudential Financial Inc. bought a new stake in shares of CRISPR Therapeutics during the 2nd quarter valued at $237,000. Finally, Invesco Ltd. raised its position in shares of CRISPR Therapeutics by 138.4% during the 2nd quarter. Invesco Ltd. now owns 66,648 shares of the company’s stock valued at $3,242,000 after purchasing an additional 38,691 shares during the period. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.